GlassScriptPhysician profile
Thomas Mark Banas
NPI 1508863051
$7,615.12
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,279 · 2020: $284 · 2021: $13.03 · 2022: $39.23.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $5,483.02 | 2019-2020 | |
| Ucb, INC. | $323.85 | 2019-2020 | |
| Allergan, INC. | $188.45 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $176.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $171.90 | 2019-2020 | |
| Merz North America, INC. | $131.96 | 2019 | |
| Emd Serono, INC. | $113.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $108.18 | 2019-2020 | |
| Genzyme Corporation | $104.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $89.32 | 2019 | |
| Boston Scientific Corporation | $83.21 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $77.79 | 2019-2020 | |
| Genentech USA, INC. | $66.19 | 2019 | |
| Aquestive Therapeutics, INC. | $58.62 | 2019 | |
| Abbvie INC. | $52.26 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $37.20 | 2019 | |
| Csl Behring | $30.93 | 2019 | |
| Adamas Pharmaceuticals, INC. | $30.27 | 2019 | |
| Biogen, INC. | $29.60 | 2019 | |
| Acorda Therapeutics, INC | $28.92 | 2019-2020 | |
| Amgen INC. | $26.92 | 2019 | |
| Eisai INC. | $25.37 | 2019 | |
| Lundbeck LLC | $23.29 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.30 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.12 | 2020 | |
| Greenwich Biosciences, INC. | $16.10 | 2019 | |
| Medtronic USA, INC. | $15.64 | 2019 | |
| Tanabe Pharma America, INC. | $14.83 | 2019 | |
| Zyla Life Sciences, INC. | $13.87 | 2019 | |
| Sk Life Science, INC. | $13.10 | 2020 | |
| Lilly USA, LLC | $12.21 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.58 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$10,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Banas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.